The Latin America, Middle East and Africa T-Cell therapy Market should witness market growth of 22.7% CAGR during the forecast period (2023-2030).
Hematological malignancies can be effectively treated using cellular therapy. In Europe, more than 40,000 allogeneic and autologous hematopoietic stem cell transplantation (HSCTs) are carried out each year. A novel T-cell therapy called chimeric antigen receptor-T (CAR-T) cells have been approved outside of clinical trials as of 2017. The antitumor activity of CAR-T cells is incredibly strong. Patients receive chemotherapy before receiving CAR-T cells, which reduces immunosuppressive cells and promotes CAR-T cell expansion.
The prevalence of cancer is rising rapidly in children as well. Acute lymphoblastic leukemia (ALL), the most prevalent malignancy in children, was a major focus of the original development of CAR T-cell treatments. While intense chemotherapy can cure more than 80% of kids with ALL that develops in B cells, there are no standard treatments for those whose tumors recur after a stem cell transplant or chemotherapy. For instance, a study team under the direction of the NCI recently published data on the long-term outcomes of children with relapsed ALL who had received CAR T-cells as part of a clinical trial.
In the Middle East, multiple myeloma (MM) is the most prevalent hematological cancer. The highest incidence of MM and related morbidity and mortality are found in Qatar and the UAE. The resource-strapped nations in this region are being severely burdened by increasing cancer morbidity rates. Several authorities in this region have admitted that handling hematological malignancies might be challenging. The development of new therapies like T-cells has considerably improved the prospects for cancer patients. Since cancer, in particular, hematological malignancies, are becoming more common in this region, the demand for T-cell therapies has increased significantly, which is advancing the regional market.
The Brazil market dominated the LAMEA T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $178.2 million by 2030. The Argentina market is estimated to grow at a CAGR of 23.3% during (2023-2030). Additionally, The UAE market would showcase a CAGR of 22.3% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Hematological malignancies can be effectively treated using cellular therapy. In Europe, more than 40,000 allogeneic and autologous hematopoietic stem cell transplantation (HSCTs) are carried out each year. A novel T-cell therapy called chimeric antigen receptor-T (CAR-T) cells have been approved outside of clinical trials as of 2017. The antitumor activity of CAR-T cells is incredibly strong. Patients receive chemotherapy before receiving CAR-T cells, which reduces immunosuppressive cells and promotes CAR-T cell expansion.
The prevalence of cancer is rising rapidly in children as well. Acute lymphoblastic leukemia (ALL), the most prevalent malignancy in children, was a major focus of the original development of CAR T-cell treatments. While intense chemotherapy can cure more than 80% of kids with ALL that develops in B cells, there are no standard treatments for those whose tumors recur after a stem cell transplant or chemotherapy. For instance, a study team under the direction of the NCI recently published data on the long-term outcomes of children with relapsed ALL who had received CAR T-cells as part of a clinical trial.
In the Middle East, multiple myeloma (MM) is the most prevalent hematological cancer. The highest incidence of MM and related morbidity and mortality are found in Qatar and the UAE. The resource-strapped nations in this region are being severely burdened by increasing cancer morbidity rates. Several authorities in this region have admitted that handling hematological malignancies might be challenging. The development of new therapies like T-cells has considerably improved the prospects for cancer patients. Since cancer, in particular, hematological malignancies, are becoming more common in this region, the demand for T-cell therapies has increased significantly, which is advancing the regional market.
The Brazil market dominated the LAMEA T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $178.2 million by 2030. The Argentina market is estimated to grow at a CAGR of 23.3% during (2023-2030). Additionally, The UAE market would showcase a CAGR of 22.3% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
By End-user
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. LAMEA T-Cell therapy Market by End User
Chapter 5. LAMEA T-Cell therapy Market by Indication
Chapter 6. LAMEA T-Cell therapy Market by Therapy Type
Chapter 7. LAMEA T-Cell therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Methodology
LOADING...
